TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24131637
Drug: Tacrolimus triple
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus triple therapy (TT) - daily tacrolimus (0.1 mg/kg divided dose), azathioprine (1 mg/kg), and prednisolone (20 mg)
Study: 16623815
Drug: Tacrolimus monotherapy
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus monotherapy (MT)
Study: 23006660
Drug: Sucralfate (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (6 g twice a day for 4 weeks)
Study: 15006216
Drug: Nurse-run telephone
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-run telephone self-management programme including six weekly mailings of OA health education modules, a relaxation audio-tape, and six weekly 45 min follow-up telephone sessions.
Study: 11557168
Drug: d-amphetamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (0.25 mg/kg) administered on days 1, 3, and 5 (AAA)
Study: 11557168
Drug: d-amphetamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (0.25 mg/kg) administered on day 5 after placebo on days 1 and 3 (PPA)
Study: 11557168
Drug: placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo administered on days 1, 3, and 5 (PPP)
Study: 7908800
Drug: Low-dose diazepam
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose diazepam (ED)
Study: 30825962
Drug: Concurrent FSRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent FSRT and alisertib (20 mg, 30 mg, 40 mg, and 50 mg BID)
Study: 30825962
Drug: Concurrent FSRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent FSRT and alisertib
Study: 30825962
Drug: Concurrent FSRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent FSRT and alisertib (50 mg cohort)
Study: 17434884
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose leuprolide injections (0.5 mg/day)
Study: 17434884
Drug: Single-dose leuprolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose leuprolide injection (1.88 mg)
Study: 12202657
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m² plus carboplatin AUC 6 (group A)
Study: 12202657
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m² plus gemcitabine 1,000 mg/m² (group B)
Study: 8942329
Drug: Propofol (20-h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (20-h infusion at 0.1 ml kg-1 h-1)
Study: 8942329
Drug: Intralipid (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid (10% as placebo, 20-h infusion at 0.1 ml kg-1 h-1)
Study: 2017470
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment with education to 'internal spontaneity', resulting in a 21% decrease in energy intake (p < 0.05) and increased fruit and nonstarchy vegetable intake.
Study: 2017470
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dietary treatment).
Study: 7081116
Drug: Test diet
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test diet (49.67 mg tin daily)
Study: 7081116
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (0.11 mg tin daily)
Study: 23725348
Drug: 2800 BAU
Normalized name: Grastek 2800 BAU Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2800 BAU Timothy grass AIT (oral lyophilisate, Phleum pratense, 75,000 SQ-T, containing approximately 15 μg of Phl p 5)
Study: 19521932
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of 20 ml of bone marrow cells (BMC) to the infarct-related artery (IRA) after primary PCI
Study: 19521932
Drug: Bare metal
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bare metal stenting of IRA without BMC administration
Study: 15385375
Drug: Large-dose calcium
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-dose calcium (15 mmol/h)
Study: 15385375
Drug: Small-dose calcium
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-dose calcium (5 mmol/h)
Study: 396659
Drug: Pirenzepine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (150 mg daily)
Study: 20208358
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 g)
Study: 26452342
Drug: Oral switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral switch therapy (OST)
Study: 26452342
Drug: Intravenous standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous standard therapy (IST)
Study: 20299956
Drug: Conjugated pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated pneumococcal vaccine (CPV) + polysaccharide pneumococcal vaccine (PPV)
Study: 20299956
Drug: Polysaccharide pneumococcal
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide pneumococcal vaccine (PPV) alone
Study: 19271025
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 60 mg/day divided into three doses for 6 months
Study: 12922095
Drug: 7VPnC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7VPnC plus DTaP‐IPV‐Hib vaccines
Study: 12922095
Drug: DTaP‐IPV‐Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP‐IPV‐Hib vaccine plus 7VPnC catch-up vaccination
Study: 11095261
Drug: BCL2 antisense
Normalized name: Exon 53 specific antisense morpholino oligonucleotide
DrugBank: Viltolarsen (DB15005)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BCL2 antisense oligonucleotides (augmerosen) plus standard dacarbazine treatment
Study: 8797612
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg BAY x 1351
Study: 8797612
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg BAY x 1351
Study: 30729631
Drug: Lecture (L)
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecture (L)
Study: 29648580
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg for 14 days) plus hypofractionated radiotherapy (40 Gy in 15 fractions)
Study: 27189086
Drug: Daily prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily prednisone (1-2 mg/kg/day for 2-4 weeks with subsequent dose reduction)
Study: 27189086
Drug: Pulsed dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pulsed dexamethasone (0.6 mg/kg/day, days 1-4 for six 3-week cycles)
Study: 28450193
Drug: Daily prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily prednisone
Study: 20592647
Drug: R-methamphetamine (R-MA)
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-methamphetamine (R-MA) 0 mg
Study: 20592647
Drug: R-methamphetamine (R-MA)
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-methamphetamine (R-MA) 1 mg
Study: 20592647
Drug: R-methamphetamine (R-MA)
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-methamphetamine (R-MA) 2.5 mg
Study: 20592647
Drug: R-methamphetamine (R-MA)
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-methamphetamine (R-MA) 5 mg
Study: 20592647
Drug: R-methamphetamine (R-MA)
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-methamphetamine (R-MA) 10 mg
Study: 20592647
Drug: R-methamphetamine (R-MA-d3)
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-methamphetamine (R-MA-d3) 2.5 mg (IV)
Study: 17296648
Drug: Esomeprazole, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole, 40 mg bid
Study: 9354200
Drug: O 20
Normalized name: ABO 201
DrugBank: ABO-201 (DB17951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: O 20 mg b.d. + C 500 mg b.d. + A 1 g b.d. for 7 days (OAC)
Study: 9354200
Drug: O 20
Normalized name: ABO 201
DrugBank: ABO-201 (DB17951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: O 20 mg b.d. + C 250 mg b.d. + M 500 mg b.d. for 7 days (MOC)
Study: 9354200
Drug: C 250
Normalized name: Cinobac 250mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: C 250 mg b.d. + M 500 mg b.d. for 7 days (CM)
Study: 9354200
Drug: A 1
Normalized name: ACA 125
DrugBank: ACA 125 (DB05489)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 1 g b.d. + clarithromycin (C) 500 mg b.d. for 7 days (AC)
Study: 9354200
Drug: O 20
Normalized name: ABO 201
DrugBank: ABO-201 (DB17951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: O 20 mg b.d. + amoxycillin (A) 1 g t.d.s. for 14 days (OA)
Study: 3333018
Drug: Calcium infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium infusions
Study: 24793366
Drug: Vaccine (succinylnorcocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (succinylnorcocaine conjugated to cholera toxin B protein)
Study: 24793366
Drug: High IgG
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High IgG group (≥42 μg/mL)
Study: 24793366
Drug: Vaccine and
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine and Placebo
Study: 23025511
Drug: OC000459 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC000459 200 mg bid
Study: 7803209
Drug: Octreotide acetate
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide acetate 0.1 mg s.c. 45 minutes before ERCP, followed by another dose 6 hours later.
Study: 28154996
Drug: Nanostructured calcium‐incorporated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanostructured calcium‐incorporated (NCI) implants
Study: 27861190
Drug: Machined (MA)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machined (MA) implants
Study: 28154996
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between NCI and MA implants
Study: 25257978
Drug: Bupropion and
Normalized name: bupropion and naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion and cognitive behavioral therapy
Study: 25771851
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg/day)
Study: 23442255
Drug: Sevelamer hydrochloride
Normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer hydrochloride (2,400 mg/day)
Study: 23885048
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg twice daily)
Study: 20688474
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (1000 IU twice daily)
Study: 19748402
Drug: Ischemic Compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ischemic Compression (IC) treatment for MTrPs
Study: 19748402
Drug: Ultrasound (US)
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound (US) treatment for MTrPs
Study: 10945088
Drug: Antidepressant trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant trials with improved blindness procedures
Study: 9127371
Drug: 2 million
Normalized name: Carticel 12 million cells/vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 million U penicillin G every 4 hours
Study: 1550533
Drug: Buccal scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal scopolamine
Study: 3299565
Drug: Ambroxol 120
Normalized name: AMBROXOL
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol 120 mg daily
Study: 3299565
Drug: Ambroxol 60
Normalized name: ambroxol 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol 60 mg daily
Study: 22240792
Drug: FOLFIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI plus bevacizumab (Bev) 5 mg kg(‐1) every 2 weeks (Arm-A)
Study: 22240792
Drug: CAPIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPIRI plus bevacizumab (Bev) 7.5 mg kg(‐1) every 3 weeks (Arm-B)
Study: 18691392
Drug: Pedometer plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pedometer plus theory-based intervention (with 20% monthly increase target)
Study: 18691392
Drug: Pedometer plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pedometer plus theory-based intervention (with 10% and 15% monthly increase targets)
Study: 15850917
Drug: Tamsulosin (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.8 mg, orally once a day)
Study: 8950881
Drug: MNrgp120 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNrgp120 vaccine
Study: 7043385
Drug: Testosterone enanthate,
Normalized name: Testosterone Enanthate, enanthate 200 mg/mL intramuscular solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate, 200 mg administered intramuscularly four times at three-week intervals
Study: 30714427
Drug: Intrauterine infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine infusion of 0.5 ml platelet-rich plasma (PRP) 48 hours before blastocyst transfer
Study: 31097515
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment in non-dipper patients
Study: 31097515
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment in dipper patients
Study: 25359163
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 (4000 IU/d)
Study: 25359163
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D3 (400 IU/d)
Study: 10731269
Drug: Intracoronary nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary nicardipine (200 mcg)
Study: 16890144
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium diet (HS) response to Ang II infusion
Study: 16890144
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (LS) response to Ang II infusion
Study: 8227112
Drug: Oral mesoglycan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mesoglycan (200 mg/day)
Study: 7926242
Drug: Goserelin depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin depot therapy for 2 months
Study: 2911851
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring program
Study: 3652932
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of the therapeutic drug monitoring program
Study: 2911851
Drug: Reinstitution of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinstitution of the therapeutic drug monitoring program
Study: 6107136
Drug: Propranolol at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol at a dose level of 1,280‐1,920 mg per day
Study: 28958651
Drug: 0.23% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.23% ropivacaine at 5 ml/h
Study: 28958651
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline at 5 ml/h
Study: 26945812
Drug: Low-fat milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat milk consumption (200 mL twice daily for 6 weeks)
Study: 22385444
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (Group B)
Study: 17714607
Drug: Ciclesonide 160
Normalized name: CICLESONIDE 160MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 160 microg once daily (CIC160 OD)
Study: 17714607
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 250 microg twice daily (FP250 BID)
Study: 12920059
Drug: CCK octapeptide
Normalized name: CCK C-terminal octapeptide
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCK octapeptide (CCK-8; 112 ng/min for 23 min) with gastric distension (300 ml)
Study: 12920059
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion with gastric distension (300 ml)
Study: 12920059
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion without gastric distension
Study: 12920059
Drug: Gastric distension
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric distension (300 ml) without CCK
Study: 11938830
Drug: Xiangsha Yangwei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiangsha Yangwei pill (XSYW)
Study: 8265515
Drug: ICI 169,369
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 169,369 30 mg
Study: 8265515
Drug: ICI 169,369
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 169,369 120 mg
Study: 24933175
Drug: Sequential photo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential photo lineup procedure
Study: 24933175
Drug: Both procedures
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both procedures (simultaneous and sequential)
Study: 3307499
Drug: Oral fructose
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fructose mineral drink
Study: 28530532
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Therapy for 8 weeks
Study: 15678363
Drug: Caffeine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (75 mg)
Study: 25761837
Drug: Caffeine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (75 mg) + L-theanine (50 mg)
Study: 25761837
Drug: L-theanine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine (50 mg)
Study: 21114493
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri DSM 17938 at a dose of 1 × 10(8) CFU per day for 30 days
Study: 7528299
Drug: nitrendipine (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitrendipine (10‐20 mg b.i.d.)
Study: 7528299
Drug: captopril (25‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril (25‐50 mg b.i.d.)
Study: 3053569
Drug: Spiramycin tablets
Normalized name: spiramycin
DrugBank: Spiramycin (DB06145)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Spiramycin tablets for 5 1/2 days
Study: 3053569
Drug: Doxycycline tablets
Normalized name: Doxycycline Tablets
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline tablets for nine days
Study: 19632716
Drug: Concurrent induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent induction chemotherapy (two cycles of cisplatin [50 mg/m(2) on days 1, 8, 29, and 36] and etoposide [50 mg/m(2) on days 1‐5 and 29‐33]) plus radiotherapy (45 Gy) followed by surgical resection if no progression.
Study: 19632716
Drug: Standard concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard concurrent chemotherapy and definitive radiotherapy without resection (up to 61 Gy).
Study: 19632716
Drug: Concurrent induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent induction chemotherapy plus radiotherapy followed by surgical resection.
Study: 19632716
Drug: Standard concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard concurrent chemotherapy and definitive radiotherapy without resection.
Study: 16541859
Drug: Acupuncture kinetotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture kinetotherapy (Acupuncture at Kaiyin point No. 1 combined with deep respiratory movement of the glottis), once daily for 5 days
Study: 16541859
Drug: Ultrasonic aerosol
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasonic aerosol inhalation of 0.9% sodium chloride injection, gentamicin sulfate injection 80,000 U and Dexamethasone injection 5mg, twice a day for 5 days
Study: 9075040
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine 3 micrograms/kg
Study: 9075040
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 4 micrograms/kg
Study: 30014865
Drug: High flavonoid
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flavonoid cocoa drink (350 mg gallic acid equivalents {GAE}/g)
Study: 30014865
Drug: Low flavonoid
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flavonoid cocoa control (120 mg GAE/g)
Study: 23571810
Drug: ABT‐925 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐925 150 mg
Study: 23571810
Drug: ABT‐925 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐925 50 mg
Study: 18844328
Drug: Yamabushitake (Hericium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yamabushitake (Hericium erinaceus) - 250 mg tablets, 4 tablets three times a day for 16 weeks
Study: 11741100
Drug: Cabergoline, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline, a long-acting dopamine agonist, dosage and duration not specified
Study: 11741100
Drug: Levodopa, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa, a dopaminergic agent, dosage and duration not specified
Study: 9682673
Drug: Half-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose aprotinin (Group 2)
Study: 9682673
Drug: Full-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose aprotinin (Group 3)
Study: 8161288
Drug: Oral fluphenazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluphenazine hydrochloride (5 mg twice daily)